Yellow fever: despite availability of a vaccine it poses a constant threat to several countries

Yellow fever: despite availability of a vaccine it poses a constant threat to several countries

 

Yellow fever is a serious hemorrhagic (bleeding) disease that may kill 15%-50% of severely infected people. Artemis One Health is conducting studies to understand the factors that would facilitate emergence of urban (within cities) yellow fever and is developing vaccine candidates that can be used to supplement the current vaccine shortage. Together with other groups we will study which mosquito species other than Aedes aegypi can be infected with the yellow fever virus. Our vaccine candidates will be based on the recombinant protein and the MVA platform (See our Approach). These platforms are convenient as they allow production of affordable vaccines that can be used in resource-poor countries.

 

What is the context of this research?

Yellow fever virus has the potential to cause big (urban) epidemics as exemplified by the situation before the 1950s. However, the majority of the reported outbreaks to date are mainly seen in Africa and South America and have a forest (sylvatic) origin. Important questions within the Health Organizations, such as WHO and PAHO are: Could yellow fever virus return to cause big epidemics again and what would be the drivers for emergence of urban epidemics of yellow fever. By conducting vector competence studies, we can understand which mosquito species are susceptible to infection with yellow fever virus and elucidate the factors that affect this susceptibility. For instance, it is known that the mosquito microbiota may modulate susceptibility to infection (competence). Of particular interest is Wolbachia, an endoparasite that colonizes only insects and limits mosquito susceptibility to infection with for instance the dengue virus. Dengue virus replication is inhibited in Aedes aegypi  colonized mosquitoes. Another example is that Aedes aegypti mosquitoes harbouring Wolbachia become resistant to Plasmodium infections, the parasite that causes malaria. Understanding the factors that influence successful establishment of yellow fever in high-risk areas such as the Caribbean and therefore its return as an urban epidemic, require fundamental knowledge both on mosquito ecology, and on host population immunity

 

What is the significance of this charity project?

Epidemic yellow fever in the Americas was successfully controlled in the mid-20th century through mass vaccination and vector reduction programmes. There is an effective vaccine against yellow fever, but in cases of big epidemics there will not be enough vaccines. In addition, the health system in many regions where urban yellow fever could be (re)established is ill-equipped to control such a disease in an epidemic form and there is an urgent need for more vaccines as part of an effective preparedness plan. Mosquito-borne infectious diseases remain the leading cause of arthropod-borne morbidity and death worldwide. The emergence and re-emergence of new mosquito-borne infectious diseases are creating unprecedented public health challenges as exemplified by recent emergence of chikungunya virus and Zika virus in the Americas. The combination of sustained introduction of viremic yellow fever travellers, a conducive ecology for local transmission, and an unimmunised population raises the possibility of yellow fever emergence in the Americas. Given the closely shared disease ecology with dengue virus and the endemic nature of dengue in many countries, the emergence of urban yellow fever remains a threat in the Americas, Asia, and Africa. Predicting emergence, spread and impact of a new mosquito-borne infectious disease such as yellow fever requires in-depth knowledge on the virus life cycle, hosts and mosquitoes, and the interplay between them. The results of this project are crucial to help countries prepare for the threat of yellow fever outbreak.

 

What are the goals?

  • Determine if different mosquito species are susceptible to infection with yellow fever virus
  • Determine if infection of  Aedes mosquitoes with other viruses such as dengue and chikungunya affects their susceptibility to infection with yellow fever virus
  • Development of candidate vaccines using state-of-the art vaccine platforms

 

Overview investment of the money

Request: Artemis One Health Research Foundation is  seeking up as much as €60.000 in funding for this charity project

Laboratory consumables  €48,300
Meetings (2,5%)     €1500
Maintanance equipment necessary for the project (2%)     €1200
Overhead (15%)     €9000
Total  €60,000

 

Use of Budget

More of 80% of the budget will be used for the actual project, which is investigating the risk that different mosquitoes can be infected with yellow fever. This part of the work includes collection of mosquitoes in the field, establishing mosquito colonies in the lab, infection experiments of mosquitoes and analyzing results. Furthermore, the budget will be used to develop new vaccine candidates that can be used to control big epidemics of yellow fever. The budget will also cover indirect costs that are crucial to perform the proposed work, which include maintenance of equipment relevant to execute the project, overhead, and meetings that are necessary to manage the project and discuss results and further steps forward. The work will start as soon as 80% of the requested funding is achieved. The duration of the project is envisioned to be 4 years.

Our researchers will share the outcomes of the experiment directly with the backer who signed in for this particular newsletter. The outcomes of this project will be published in the form of peer-reviewed journal publication, open data sets, graduate theses, academic posters, and more.

budget

Artemis One Health Research Foundation depends to a great extent on the support and generosity of donors for the success of our research projects. To guarantee that more than 80% of the donations goes to research, we need another source of funding to cover the salary for a technician to do the work. For this specific project we are seeking support for one technician for the duration of 4 years. The costs for personnel are estimated at 43,940 euro per year. Note that such a technician can be used for max three of the project lines of Artemis. In the face of lack of support for personnel, we will cover the personnel costs from own investments. However as a foundation relying on donations for specific programs we will appreciate your generosity to help us cover the personnel cost of this project. Are you a strong believer in our mission and do you/your organization want to support us in this fight, please feel free to contact our head Research & Development, Dr. Byron Martina by email b.martina@artemisonehealth.com or office phone +31 (0)30 635 5444.

 

WE NEED YOUR HELP! DONATE & SHARE this charity project and make people aware

 

* Please read these Terms & Conditions carefully. By donating you are agreeing to these terms and conditions. If you have any queries regarding our Charity Donation Services, please contact our Fundraising Officer, by email e.martina@artemisonehealth.com or office phone +31 (0)30 635 5444.

 

 

Subscribe to our mailing list

* indicates required



Select Research projects


Elephant herpesvirus: killing up to 90% of severely  affected animals

Elephant herpesvirus: killing up to 90% of severely affected animals

 

 

Elephant endotheliotropic herpes virus (EEHV) can infect and cause mortality in captive and wild elephants posing a threat to the continuation and success of captive breeding programs for the highly endangered Asian elephant in both North American and European zoos. As a result, development of a safe and effective vaccine has high priority and will have a great impact on the health of captive elephants, safe geographic translocations and successful continuation of breeding programs. Artemis One Health has been focusing on the development of an ELISA that can be used to study the epidemiology of the disease, and the development of a safe and effective vaccine. In order to achieve both tasks Artemis is working on producing the glycoprotein B (gB) and N (gN) of the virus. A test was developed using the gB protein to first monitor the presence of the virus in elephant herds in several zoos. However, the amount of gB that we managed to produce is not enough or sufficiently pure to allow large scale studies. Therefore, currently we are using a novel protein expression platform (Leishmania tarentolae) to produce the gB and gN protein which will be used for the development of a new generation serological test and a potential candidate vaccine.

elephant-asian_artemis-one-health-elephant-herpes-virus   animal-save-elephants-elephant-herpesvirus-artemis_

What is the context of this research?

EEHV can cause a highly fatal hemorrhagic disease (bleeding disease) in young Asian elephants, like Ebola in humans, often affecting those born in captivity, and killing up to 90% of severely affected animals. Since 1995, over fifty disease cases have been documented in North America and Europe, of which only nine have been successfully cured. As it is difficult to cure EEHV bleeding disease, a safe and effective vaccine currently represents the most feasible strategy in combating this disease. The glycoprotein N of EEHV is highly immunogenic and represents a plausible candidate protein for a vaccine against EEHV. The Leishmania protein expression system (LEXSY; Jena Bioscience GmbH), based on the lizard parasite Leishmania tarentolae, has been described in the literature for its ability to efficiently express proteins at a large scale, but also for its ability to add the right sugar groups to protein, allowing them to closely resemble their native form. As a result, expression of gN using the Leishmania platform is likely to increase the chance of this protein to induce an effective immune response.

 elephant-asian-elephant-herpesvirus-artemis-one-health-eehv_    elephant-extinction-save-elephants-artemis-one-health_

What is the significance of this charity project?

The elephant is one of the most recognized and beloved animal species and is listed by the World Conservation Union as a critically endangered species. Captive breeding is the only source for replacing elephants at zoos and for maintaining the genetic diversity of captive populations. EEHV can kill up to 90% of severely affected animals, including baby elephants, the virus represents an additional threat to the propagation of an animal species that is already highly endangered due to human behaviour, such as poaching and habitat destruction. Vaccination of captive elephants represents the most plausible and cost-effective strategy for combating EEHV-related deaths and increasing the survival of this important animal species. Producing a highly immunogenic protein of EEHV at a large scale brings us one step closer to the development of an effective vaccine.

 

What are the goals?

  • Expression and purification of gB and gN in Leishmania tarentola.
  • Testing the antigenicity of the protein in an ELISA using sera from EEHV-infected zoo elephants.
  • Development of a safe and effective vaccine against EEHV.

 

Overview investment of the money

Request: Artemis One Health Research Foundation is  seeking up as much as €30.000 in funding for this charity project

Laboratory consumables  € 24,150
Meetings (2,5%)        €750
Maintanance equipment necessary for the project (2%)        €600
Overhead (15%)      €4500
Total   €30,000

 

Use of Budget

More of 80% of the budget will be used to the actual project, which is the development of the serological test to be able to diagnose infection with EEHV and development of an effective vaccine against EEHV. The laboratory work includes producing the protein in large quantities and purification of the protein. Subsequently the protein will be used to develop a reliable test to detect antibodies against the virus in blood of elephants. In addition, work will be done to produce and test an effective candidate vaccine against EEHV. The budget will also cover indirect costs that are crucial to perform the proposed work, which include maintenance of equipment relevant to execute the project, overhead, and meetings that are necessary to manage the project and discuss results and further steps forward. The work will start as soon as 80% of the requested funding is achieved. The duration of the project is envisioned to be 3 years.

Our researchers will share the outcomes of the experiment directly with the backer who signed in for this particular newsletter. The outcomes of this project will be published in the form of peer-reviewed journal publication, open data sets, graduate theses, academic posters, and more.
budget EEHV

Artemis One Health Research Foundation depends to a great extent on the support and generosity of donors for the success of our research projects. To guarantee that more than 80% of the donations goes to research, we need another source of funding to cover the salary for a technician to do the work. For this specific project we are seeking support for one technician for the duration of 3 years. The costs for personnel are estimated at 43,940 euro per year. Note that such a technician can be used for max three of the project lines of Artemis. In the face of lack of support for personnel, we will cover the personnel costs from own investments. However as a foundation relying on donations for specific programs we will appreciate your generosity to help us cover the personnel cost of this project. Are you a strong believer in our mission and do you/your organization want to support us in this fight, please feel free to contact our head Research & Development, Dr. Byron Martina by email b.martina@artemisonehealth.com or office phone +31 (0)30 635 5444.

 

RECEIVE THIS FREE GIFT (donations ≥ €35,-)

Donate TODAY and receive this free elephant keychain as our modest way to thank you for supporting our fight against the elephant endotheliotropic herpes virus.

 
 
 
 
 

WE NEED YOUR HELP! DONATE & SHARE this charity project and make people aware

* Please read these Terms & Conditions carefully. By donating you are agreeing to these terms and conditions. If you have any queries regarding our Charity Donation Services, please contact our Fundraising Officer, by email e.martina@artemisonehealth.com or office phone +31 (0)30 635 5444.

 

 

 

Subscribe to our mailing list

* indicates required



Select Research projects


Chikungunya

Chikungunya

 Chikungunya is a disease characterized by incapacitating pain in the joints and muscles, and no treatment or vaccine is currently available. The only way to prevent chikungunya is to prevent mosquito bites, something that is impossible to achieve over a long period of time. Although 50% of infected patients recover completely with no complications, another 50% will develop chronic pain or inflammation in the joints and/or muscles, which may last for months to years, resulting in additional psychological problems. During an outbreak, the burden on health services and the impact of the debilitating symptoms on the economy is immense. Chronic symptoms disrupt daily lives, require multiple medical visits to the physician, and about 80% of patients take medications every day to manage their symptoms. Understanding the mechanism of chronic chikungunya will help with the development of drugs that target the immune response or the virus to treat this chronic, debilitating disease. Artemis has identified potential pathogenic pathways that pave the way to the development of effective therapies.

Chikungunya has emerged in the Americas in 2013. The virus was responsible for huge morbidity, manifested as acute, debilitating muscle and joint pain and up to 50% of patients remained with chronic pain for months to years after infection. Chikungunya resembles the autoimmune disease “rheumatoid arthritis” and it is not possible to predict who will develop chronic arthritis as the mechanism that leads to the chronic disease is not well-understood. In this project we will look into the role of macrophages in the development of chronic disease.

 

What is the context of this research?

It is believed that infection of macrophages results in low-grade persistent infection. The continuous production of virus or the reaction of the macrophages to the low-grade infection may be responsible for the chronic pain and inflammation seen in 30-50% of patients.

 

What is the significance of this charity project?

Understanding the mechanism of chronic disease has big advantages to the patient. First, it may allow identification of biomarkers for predicting who will develop chronic disease. In addition, understanding the process by which chronic disease develops may pave the way to the development of effective treatment. Chikungunya outbreaks and the development of chronic disease have a huge impact on the health care system and a negative impact on the economy. It is extremely important to invest in research focussing on understanding the mechanism of chronic disease, which may help us design ways to prevent or treat it.

 

What are the goals?

  • Identify biomarkers of chronic chikungunya in cohorts of patients from the Dutch Caribbean
  • Understanding the role of macrophages in development of chronic disease

 

Overview investment of the money

Request: Artemis One Health Research Foundation is  seeking up as much as €30.000 in funding for this charity project

Laboratory consumables   €24,150
Meetings (2,5%)        €750
Maintanance equipment necessary for the project (2%)        €600
Overhead (15%)      €4500
Total   €30,000

Use of Budget

More of 80% of the budget will be used for the actual project, which is investigating the role of the immune system in development of chronic joint inflammation and pain. This part of the work includes experiments in the lab using different cells form human origins. Budget will be used to purchase cell cultures consumables, medium, monoclonal antibodies, and biomarker assays. The budget will also cover indirect costs that are crucial to perform the proposed work, which include maintenance of equipment relevant to execute the project, overhead, and meetings that are necessary to manage the project and discuss results and further steps forward. The work will start as soon as 80% of the requested funding is achieved. The duration of the project is envisioned to be 4 years.

Our researchers will share the outcomes of the experiment directly with the backer who signed in for this particular newsletter. The outcomes of this project will be published in the form of peer-reviewed journal publication, open data sets, graduate theses, academic posters, and more.

budget

Artemis One Health Research Foundation depends to a great extent on the support and generosity of donors for the success of our research projects. To guarantee that more than 80% of the donations goes to research, we need another source of funding to cover the salary for a technician to do the work. For this specific project we are seeking support for one technician for the duration of 4 years. The costs for personnel are estimated at 43,940 euro per year. Note that such a technician can be used for max three of the project lines of Artemis. In the face of lack of support for personnel, we will cover the personnel costs from own investments. However as a foundation relying on donations for specific programs we will appreciate your generosity to help us cover the personnel cost of this project. Are you a strong believer in our mission and do you/your organization want to support us in this fight, please feel free to contact our head Research & Development, Dr. Byron Martina by email b.martina@artemisonehealth.com or office phone +31 (0)30 635 5444.

 

WE NEED YOUR HELP! DONATE & SHARE this charity project and make people aware

 

* Please read these Terms & Conditions carefully. By donating you are agreeing to these terms and conditions. If you have any queries regarding our Charity Donation Services, please contact our Fundraising Officer, by email e.martina@artemisonehealth.com or office phone +31 (0)30 635 5444.

 

 

 

Subscribe to our mailing list

* indicates required



Select Research projects


Zika threatens more than just the unborn developing baby

Zika threatens more than just the unborn developing baby

 Zika was long considered not relevant and not worth investigating. However, the emergence of the virus in the Americas made it painfully clear that the virus is more dangerous than scientists reckoned a short time ago. There is a risk of spread of Zika virus disease in the European Region but this risk varies from country to country. The virus is associated with birth defects and evidence is accumulating that the virus is indeed the cause of malformations in unborn babies. Several viruses may cause birth defects and the most dangerous time appears to be earlier in the pregnancy, when damage to just a few cells has large consequences. However, there is evidence that infection with Zika virus at any point during a pregnancy can endanger the baby. Even asymptomatic infections, which occur in up to 75% of cases, are still dangerous to the unborn child. Babies with severe birth defects have been born to women who experienced asymptomatic infections, and therefore, the fear of an invisible epidemic of birth defects is substantial. It is not clear why Zika spread so quickly throughout the Americas and whether some factors may have facilitated this process. Since other viruses similar to Zika circulate in the affected areas, it is likely that cross-reactivity between Zika and other similar viruses play an important role. If proven, this will have have a huge impact on the use of vaccines against dengue or Zika. 

In February 2016, the Zika virus outbreak has been declared a public health emergency of international concern (PHEIC) by the World Health Organization (WHO). The emergence of Zika in the Americas was associated with severe complications such as microcephaly and Guillain-Barré syndrome (GBS). Although several studies have confirmed the association of Zika virus infection with microcephaly, several things remain unknown. This project aims at understanding the long-term effects in children born from mothers that were infected during pregnancy, but have not developed microcephaly.

 

What is the context of this research?

The currently on-going Zika virus epidemic has rapidly spread throughout South and Central America. Infection with Zika virus has not only been associated with relatively mild clinical disease, but recently also appeared to be associated with neurological disease manifestations that had not been reported before: microcephaly in unborn babies, Guillain-Barré Syndrome, and encephalitis. There is also recent evidence that Zika virus may be associated with miscarriage as well. However, not all children born from mothers infected with Zika virus during pregnancy develop microcephaly and it is less clear what the long-term effects will be in these children. For example, development of other neurological problems, such as epilepsy has been associated with infection of children with neurotropic viruses, such as herpes simplex virus. Infection of mice with neurotropic viruses also provided evidence that brain infection is linked to development of epileptic seizures.

 

What is the significance of this charity project?

It is not known what the long-term consequences of the Zika epidemic in the Americas are. If pre-natal or neonatal infection with Zika increases the chance of developing neurological disorders such as epilepsy, it may have a huge economical impact and prevention of infection becomes crucial.

 

What are the goals?

  • Determine the long-term consequences of pre-natal and neonatal Zika virus infection in a prospective cohort in the Dutch Caribbean
  • Study the effect of brain infection on development of epilepsy in the mouse model

 

Overview investment of the money

Request: Artemis One Health Research Foundation is  seeking up as much as €60.000 in funding for this charity project

Laboratory consumables   €48,300
Meetings (2,5%)      €1500
Maintanance equipment necessary for the project (2%)      €1200
Overhead (15%)      €9000
Total   €60,000

 

Use of Budget

More of 80% of the budget will be used for the actual project, which is investigating the risk of neonatal Zika virus infection in development of epilepsy. The work includes experimental studies where animal models will be used to study the role of Zika virus infection in development of epilepsy. Money will be used to finance request for permits to perform infection experiments in animal models, purchase and housing of animals and analysis of results. In addition, children borne from mothers that were infected during pregnancy will be followed for four years to determine the association of Zika virus infection and development of epilepsy and other cognitive disorders. The budget will be used to perform enquiries, blood collection and its analysis and analyzing results. The budget will also cover indirect costs that are crucial to perform the proposed work, which include maintenance of equipment relevant to execute the project, overhead, and meetings that are necessary to manage the project and discuss results and further steps forward. The work will start as soon as 80% of the requested funding is achieved. The duration of the project is envisioned to be 5 years.

Our researchers will share the outcomes of the experiment directly with the backer who signed in for this particular newsletter. The outcomes of this project will be published in the form of peer-reviewed journal publication, open data sets, graduate theses, academic posters, and more.

budget

Artemis One Health Research Foundation depends to a great extent on the support and generosity of donors for the success of our research projects. To guarantee that more than 80% of the donations goes to research, we need another source of funding to cover the salary for a technician to do the work. For this specific project we are seeking support for one technician for the duration of 5 years. The costs for personnel are estimated at 43,940 euro per year. Note that such a technician can be used for max three of the project lines of Artemis. In the face of lack of support for personnel, we will cover the personnel costs from own investments. However as a foundation relying on donations for specific programs we will appreciate your generosity to help us cover the personnel cost of this project. Are you a strong believer in our mission and do you/your organization want to support us in this fight, please feel free to contact our head Research & Development, Dr. Byron Martina by email b.martina@artemisonehealth.com or office phone +31 (0)30 635 5444.

 

WE NEED YOUR HELP! DONATE & SHARE this charity project and make people aware

 

* Please read these Terms & Conditions carefully. By donating you are agreeing to these terms and conditions. If you have any queries regarding our Charity Donation Services, please contact our Fundraising Officer, by email e.martina@artemisonehealth.com or office phone +31 (0)30 635 5444.

 

 

 

Subscribe to our mailing list

* indicates required



Select Research projects


Rabies treatment for “ALL”

Rabies treatment for “ALL”

 When viruses infect a cell, they take over its cellular machinery for the purpose of creating more copies of itself. Rabies virus specifically infects neurons in the brain leading to neuron dysfuction and death. As a result of infection, cells in the brain reacts and try to resolve the infection, leading to more damage. There are a handful of drugs that combat specific viruses, but no drugs are available to treat rabies. As a consequence, patients infected with rabies that did not receive the vaccine and immunoglobulins within 48 hours of infection will inevitably die. The only way to save these patients is by having drugs that can inhibit virus replication and mitigate the detrimental immune response to the infection at the same time. Combining a therapeutic approach targeting both components is a novel and very promising approach that Artemis is pursuing. 

 

The mechanism of disease (pathogenesis) for rabies encephalitis is not well understood. Rabies is the deadliest virus known to mankind. Some of the clinical manifestations of rabies include fear of water (hydrophobia) and air (aerophobia). Once a patient develops clinical disease, he/she will certainly die as a result of the infection. To date, 100% of infected individuals die of infection and this cannot be prevented. It is extremely important to have medicines to treat un vaccinated individuals, which is not only important to the developing countries where rabies is a real problem, but also to the developed countries where imported cases have been reported. Artemis One Health has used state-of-the-art technology to decipher some of the pathways involved in the pathogenic process of fatal rabies encephalitis. Furthermore, Artemis has discovered a protein that can naturally target the viral RNA and inhibit virus replication. In this project, Artemis will build on preliminary data and focus on optimising the specificity of the anti-rabies protein to eventually develop a safe and effective anti-rabies treatment.

 

 What is the context of this research?

Rabies kills more than 60,000 people each year, mainly children in the developing countries. Many of these infections could have been prevented or many infected individuals could have been helped if vaccine and immunoglobulin preparations were available at an affordable price. However, it is unrealistic to expect that tourists or even local people will be vaccinated. Alternatively, it might not be obvious that contact with an animal resulted in infection. Therefore, it is of paramount importance to have effective medicines, which can be used to treat infected patients that are too late to receive the vaccine. In order to develop effective medicines, more research needs to be conducted on rabies pathogenesis. In addition, it is crucial to find ways to inhibit virus replication, which is the most important trigger of the downstream pathogenic reactions.

 

 What is the significance of this charity project?

Availability of effective medicines will save the lives of thousands of infected individuals. This research has implications for the whole neuro-infectiology field and the field of neuro-degenerative disease such as Alzheimer and Parkinson’s disease.

 

What are the goals?

  • Further validate the anti-rabies compound
  • Optimise the specificity of the anti-rabies compound for rabies virus infected cells
  • Perform efficacy tests in vitro cell models
  • Perform efficacy tests in appropriate animals models

 

Overview investment of the money

Request: Artemis One Health Research Foundation is  seeking up as much as €60.000 in funding for this charity project

Laboratory consumables   €48,300
Meetings (2,5%)      €1500
Maintanance equipment necessary for the project (2%)      €1200
Overhead (15%)      €9000
Total   €60,000

Use of Budget

The process leading to development of a safe and effective medicine against rabies is a long and expensive process, divided into 1) proof-of-concept-selection, 2) proof-of-concept-optimization, 3) preclinical evaluation, 4) clinical trials. However, we owe it to our fellow human beings to develop medicines that can save the lives of infected patients that are too late to receive and benefit from the vaccine. The first and most important phase in this long process is finding and optimizing a candidate anti-rabies compound in vitro and in animals (stages 1, 2 and 3). To date, no one has managed to develop an anti-rabies compound that proved to be effective in animals and could therefore be tested in clinical trials. The goal of Artemis is to participate in development and optimizing candidate anti-rabies compounds (stage 1, 2, and 3). We have developed a candidate anti-rabies that showed promising inhibitory effect in vitro. Therefore, the next crucial step is to make different variants of the compound and select the most promising candidate for further testing in pre-clinical settings. This campaign is meant to raise money to finalize stage 1. Since this stage of the project is crucial in the endeavors to find an effective medicine against rabies, it represents a permanent line of our rabies research line. To ensure that this stage can be successfully done, we need approximately 60,000 euro. To be able to start this stage of the project, we need a minimum of 20,000 euro but since our goal is to successfully finalize this stage, the campaign will continue until the complete budget is obtained.

More of 80% of the budget will be used for the actual research, which is the further optimization of our first candidate vaccine against rabies.

This part of the work includes producing several candidate medicines (anti-rabies compounds). The budget will be used to:

  1. Purchase consumables for design and production of several candidate anti-rabies proteins.
  2. Optimization the protein to make it safe. It is a requirement that compound to be tested in preclinical settings must be safe. A significant amount of time should be invested in this phase to ensure development of medicines that are safe and with little side-effects.
  3. Consumables for cell culture experiments to test the efficacy of several candidate proteins for their ability to inhibit rabies virus replication.
  4. Analysis of results and preparation for a second round of pre-clinical studies. Proper analysis of the results needs sophisticated tools such as laboratory associated immune correlates of protection, statistical analysis, and in silico-modeling.
  5. The budget will also cover indirect costs that are crucial to perform the proposed work, which include maintenance of equipment relevant to execute the project, overhead, and meetings that are necessary to manage the project and discuss results and further steps forward. The work will start as soon as 30% of the requested funding is achieved. The duration of the stage 2 of the project is envisioned to be 4 years.

 

In order to show our commitment to the project we will contribute with 10% of the budget from our own investment. To further ensure that we will raise minimum of 30% of the budget or the complete budget needed to finish stage 2, will invest all our time and energy to find extra support for our campaign from companies and philanthropists. If after two year from start of the campaign we do not manage to raise at least 20,000 euro, we will either use the money to support our first rabies campaign (vaccine development) or donate the collected money to the Sharon Live On Foundation (www.sharonliveon.org/), a foundation opened by the parents that tragically lost their daughter to rabies. They started this foundation to address the shortages of rabies vaccine in Kenya and to ensure that more Kenyans know about the dangers of rabies.

Our researchers will share the outcomes of the experiment directly with the backer who signed in for this particular newsletter. The outcomes of this project will be published in the form of peer-reviewed journal publication, open data sets, graduate theses, academic posters, and more.

budget

Artemis One Health Research Foundation depends to a great extent on the support and generosity of donors for the success of our research projects. To guarantee that more than 80% of the donations goes to research, we need another source of funding to cover the salary for a technician to do the work. For this specific project we are seeking support for one technician for the duration of 4 years. The costs for personnel are estimated at 43,940 euro per year. Note that such a technician can be used for max three of the project lines of Artemis. In the face of lack of support for personnel, we will cover the personnel costs from own investments. However as a foundation relying on donations for specific programs we will appreciate your generosity to help us cover the personnel cost of this project. Are you a strong believer in our mission and do you/your organization want to support us in this fight, please feel free to contact our head Research & Development, Dr. Byron Martina by email b.martina@artemisonehealth.com or office phone +31 (0)30 635 5444.

 

WE NEED YOUR HELP! DONATE & SHARE this charity project and make people aware

* Please read these Terms & Conditions carefully. By donating you are agreeing to these terms and conditions. If you have any queries regarding our Charity Donation Services, please contact our Fundraising Officer, by email e.martina@artemisonehealth.com or office phone +31 (0)30 635 5444.

Subscribe to our mailing list

* indicates required



Select Campaigns


Rabies vaccines and immunoglobulins: “Affordable” and accessible for the “POOR”

Rabies vaccines and immunoglobulins: “Affordable” and accessible for the “POOR”

Rabies is the most deadly viral disease known today and 3 BILLION PEOPLE IN THE WORLD ARE AT RISK of contracting the disease. MORE THAN 60,000 PEOPLE DIE of rabies each year because they cannot get the care they need. That is equivalent to 1 person dying of rabies every 9 minutes or 160 people per day. Most of these deaths occurs in Africa and Asia, the poorest continents in the world, and nearly half of the victims are children under the age of 15. Many of these lives can be saved if bite victims and healthcare providers know what to do and have what they need —rabies vaccine and immunoglobulin. However, these life-saving therapeutics are way too expensive for these people, meaning that the majority dies.  

 

Rabies is the deadliest virus known to mankind. Some of the clinical manifestations of rabies include fear of water (hydrophobia) and air (aerophobia). The mechanism of disease (pathogenesis) for rabies encephalitis is not well understood. However, infection and its deadly consequences can be prevented with a vaccine. Once bitten by an infected dog, infection can still be prevented if non-vaccinated patients receive vaccination and anti-serum (immunoglubulins) within 48 hours. Unfortunately, both the vaccine and the immunoglobulin preparations are too expensive for the poor. With this project, Artemis One Health will work on the development of safe and affordable candidate vaccines and immunoglobulins against rabies.

 

 What is the context of this research?

Although rabies is 99,9% fatal, it is also 100% preventable IF VACCINES ARE USED. In order to protect the population at risk from an agonizing death there is a need for safe, potent and affordable vaccines that can be widely available in these areas. Rabies kills more than 60,000 people each year, mainly children in the developing countries. Many of these infections could have been prevented or many infected individuals could have been helped if vaccine and immunoglobulin preparations were available at an affordable price. However, the current platforms for the production of these agents are complex and expensive.

 

 What is the significance of this charity project?

Availability of affordable vaccines and immunoglobulins will save thousands of lives. Development of the platform for production of cheap and effective vaccines and immunoglobulins is also important if we want to produce these agents against other neglected diseases.

 

What are the goals?

  • Develop candidate vaccines and immunoglobulins that are more effective than the currently available ones.
  • Develop methodological and marketing strategies to produce cheap vaccines and immunoglobulins

 

Overview investment of the money

Request: Artemis One Health Research Foundation is  seeking up as much as €60.000 in funding for this charity project

Laboratory consumables   €48,300
Meetings (2,5%)      €1500
Maintanance equipment necessary for the project (2%)      €1200
Overhead (15%)      €9000
Total   €60,000

 

Use of Budget

Rabies disease results in an estimated $8.6 billion of economic losses annually, and the most cost-effective way to stop rabies is vaccination. The process leading to development of a safe and effective vaccine against rabies can be divided into four stages: 1) proof-of-concept-selection, 2) proof-of-concept-optimization, 3) preclinical evaluation, 4) clinical trials. Artemis is committed to finalize the first three stages of this process. We already successfully finished stage 1, where we developed an effective candidate vaccine that protects animals from deadly infection. This first vaccine was published recently in a scientific peer-reviewed journal (https://www.ncbi.nlm.nih.gov/pubmed/24962755). THIS CAMPAIGN IS MEANT TO RAISE MONEY TO FINALIZE STAGE 2. Since this stage of the project is crucial in the fight against rabies, it represents a permanent line of our rabies research line. To ensure that this stage can be successfully done, we need approximately 60,000 euro. To be able to start this stage of the project, we need a minimum of 20,000 euro but since our goal is to successfully finalize this stage, the campaign will continue until the complete budget is obtained.

More of 80% of the budget will be used for the actual research, which is the further optimization of our first candidate vaccine against rabies. The vaccine is intended for those that need it the most, particularly children living in resource-poor countries. This part of the work includes producing several optimized versions of the candidate vaccines. The work consists of:

  • Produce and purify several versions of the rabies virus protein, and finding the most optimal version of the protein is the determinant of a successful vaccine.
  • Purchase and housing of mice to test the vaccine candidates. Clearly the best vaccine will be the one able to provide protection after only one shot of the vaccine.
  • Develop in vitro assays that allow future evaluation of the vaccine in animal-free systems.
  • Analysis of results and preparation for a second round of pre-clinical studies. Proper analysis of the results needs sophisticated tools such as laboratory associated immune correlates of protection, statistical analysis, and modeling.
  • The budget will also cover indirect costs that are crucial to perform the proposed work, which include maintenance of equipment relevant to execute the project, overhead, and meetings that are necessary to manage the project and discuss results and further steps forward. The work will start as soon as 30% of the requested funding is achieved. The duration of the stage 2 of the project is envisioned to be 4 years.

In order to show our commitment to the project we will contribute 10% of the budget from our own investment. To further ensure that we will raise minimum of 30% of the budget or the complete budget needed to finish stage 2, will invest all our time and energy to find extra support for our campaign from companies and philanthropists. If after two years from start of the campaign we do not manage to raise at least 20,000 euro, we will either use the money to support our second rabies campaign (Development of an anti-rabies treatment) or donate the collected money to the Sharon Live On Foundation (www.sharonliveon.org/), a foundation opened by the parents that tragically lost their daughter to rabies. They started this foundation to address the shortages of rabies vaccine in Kenya and to ensure that more Kenyans know about the dangers of rabies.

Our researchers will share the outcomes of the experiment directly with the backer who signed in for this particular newsletter. The outcomes of this project will be published in the form of peer-reviewed journal publication, open data sets, graduate theses, academic posters, and more.

budget

Artemis One Health Research Foundation depends to a great extent on the support and generosity of donors for the success of our research projects. To guarantee that more than 80% of the donations go to research, we need another source of funding to cover the salary for a technician to do the work. For this specific project we are seeking support for one technician for the duration of 4 years. The costs for personnel are estimated at 43,940 euro per year. Note that such a technician can be used for max three of the project lines of Artemis. In the face of lack of support for personnel, we will cover the personnel costs from own investments. However, as a foundation relying on donations for specific programs, we will appreciate your generosity to help us cover the personnel cost of this project. Are you a strong believer in our mission and do you/your organization want to support us in this fight, please feel free to contact our head Research & Development, Dr. Byron Martina by email b.martina@artemisonehealth.com or office phone +31306355444.

 

WE NEED YOUR HELP! DONATE & SHARE this charity project and make people aware

 

* Please read these Terms & Conditions carefully. By donating you are agreeing to these terms and conditions. If you have any queries regarding our Charity Donation Services, please contact our Fundraising Officer, by email e.martina@artemisonehealth.com or office phone +31 (0)30 635 5444.

 

 

 

 

 

Subscribe to our mailing list

* indicates required



Select Campaigns


Font resize
Contrast
X